RU97101109A - APPLICATION OF GABAPENTIN FOR TREATMENT OF FEAR AND PANIC CONDITIONS - Google Patents
APPLICATION OF GABAPENTIN FOR TREATMENT OF FEAR AND PANIC CONDITIONSInfo
- Publication number
- RU97101109A RU97101109A RU97101109/14A RU97101109A RU97101109A RU 97101109 A RU97101109 A RU 97101109A RU 97101109/14 A RU97101109/14 A RU 97101109/14A RU 97101109 A RU97101109 A RU 97101109A RU 97101109 A RU97101109 A RU 97101109A
- Authority
- RU
- Russia
- Prior art keywords
- gabapentin
- compound
- pharmaceutically acceptable
- acceptable salt
- treatment
- Prior art date
Links
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 title claims 3
- 229960002870 gabapentin Drugs 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 102000024070 binding proteins Human genes 0.000 claims 1
- 108091007650 binding proteins Proteins 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Claims (7)
в которой R1 означает водород или низший алкил, а n означает 4,5 или 6 либо его фармацевтически приемлемой соли в форме дозировочной единицы млекопитающим, нуждающимся в упомянутом лечении.1. A method of treating a condition of fear, comprising administering a therapeutically effective amount of a compound of formula
in which R 1 means hydrogen or lower alkyl, and n means 4,5 or 6 or its pharmaceutically acceptable salt in the form of a dosage unit to a mammal in need of said treatment.
в которой R1 означает водород или низший алкил, а n означает 4,5 или 6 либо его фармацевтически приемлемой соли в форме дозировочной единицы млекопитающим, нуждающимся в упомянутом лечении.2. A method of treating and / or preventing a state of panic, comprising administering a therapeutically effective amount of a compound of the formula
in which R 1 means hydrogen or lower alkyl, and n means 4,5 or 6 or its pharmaceutically acceptable salt in the form of a dosage unit to a mammal in need of said treatment.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28128594A | 1994-07-27 | 1994-07-27 | |
US08/281,285 | 1994-07-27 | ||
US08/281.285 | 1994-07-27 | ||
US08/445,398 | 1995-06-06 | ||
US08/445,398 US5792796A (en) | 1994-07-27 | 1995-06-06 | Methods for treating anxiety and panic |
US08/445.398 | 1995-06-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU97101109A true RU97101109A (en) | 1999-04-10 |
RU2168982C2 RU2168982C2 (en) | 2001-06-20 |
Family
ID=26960801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU97101109/14A RU2168982C2 (en) | 1994-07-27 | 1995-07-11 | Method of treatment of patients with fear state or treatment and/or prophylaxis of panic state, purified protein able to bind gabapentin and pharmaceutical composition showing sedative, antipanic and anticonvulsant effects |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0804182B1 (en) |
JP (1) | JPH10503490A (en) |
AT (1) | ATE218334T1 (en) |
AU (1) | AU703428B2 (en) |
CA (1) | CA2193384C (en) |
CZ (1) | CZ291757B6 (en) |
DE (1) | DE69526972T2 (en) |
DK (1) | DK0804182T3 (en) |
ES (1) | ES2176334T3 (en) |
HU (4) | HU0102041D0 (en) |
MX (1) | MX9606674A (en) |
NZ (1) | NZ290050A (en) |
PL (1) | PL187064B1 (en) |
PT (1) | PT804182E (en) |
RO (1) | RO120041B1 (en) |
RU (1) | RU2168982C2 (en) |
SK (1) | SK283711B6 (en) |
WO (1) | WO1996003122A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712158A (en) * | 1995-06-06 | 1998-01-27 | Warner-Lambert Company | Cell line for the rapid expression of functional calcium channels |
US6372792B1 (en) | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
CN1094757C (en) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | Isobutylgaba and its derivatives for the treatment of pain |
DE69834204T2 (en) | 1997-10-27 | 2007-03-29 | Warner-Lambert Co. Llc | CYCLIC AMINO ACIDS AND DERIVATIVES AS MEDICAMENTS |
BR9910697A (en) | 1998-05-26 | 2001-01-30 | Warner Lambert Co | Structurally compressed amino acid compounds having affinity for the alpha2delta subunit of a calcium channel |
FR2781793B1 (en) | 1998-08-03 | 2001-07-20 | Prographarm Lab | PROCESS FOR PRODUCING COATED GABAPENTINE GRANULES |
EP1214599A2 (en) * | 1999-09-16 | 2002-06-19 | Warner-Lambert Company | Screening for alpha2delta-1 subunit binding ligands |
RU2458049C2 (en) * | 2003-09-17 | 2012-08-10 | Ксенопорт, Инк. | Treatment and prevention of restless leg syndrome with using gaba analogue prodrugs |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2016465A1 (en) * | 1989-06-02 | 1990-12-02 | Zola Phillip Horovitz | Method for preventing or treating anxiety employing a calcium channel blocker |
US5189026A (en) * | 1991-06-07 | 1993-02-23 | Fractal Laboratories, Inc. | Treatment of human diseases involving dysregulation or dysfunction of the nervous system |
JP3856816B2 (en) * | 1992-05-20 | 2006-12-13 | ノースウェスターン ユニヴァーシティ | GABA and L-glutamic acid analogs for anti-seizure treatment |
-
1995
- 1995-07-11 HU HU0102041A patent/HU0102041D0/en unknown
- 1995-07-11 ES ES95926249T patent/ES2176334T3/en not_active Expired - Lifetime
- 1995-07-11 CA CA002193384A patent/CA2193384C/en not_active Expired - Fee Related
- 1995-07-11 MX MX9606674A patent/MX9606674A/en active IP Right Grant
- 1995-07-11 CZ CZ1997162A patent/CZ291757B6/en not_active IP Right Cessation
- 1995-07-11 SK SK90-97A patent/SK283711B6/en unknown
- 1995-07-11 HU HU0102043A patent/HU0102043D0/en unknown
- 1995-07-11 JP JP8505766A patent/JPH10503490A/en not_active Ceased
- 1995-07-11 PL PL95318268A patent/PL187064B1/en not_active IP Right Cessation
- 1995-07-11 PT PT95926249T patent/PT804182E/en unknown
- 1995-07-11 WO PCT/US1995/008702 patent/WO1996003122A2/en active IP Right Grant
- 1995-07-11 DE DE69526972T patent/DE69526972T2/en not_active Expired - Fee Related
- 1995-07-11 HU HU0102040A patent/HU0102040D0/en unknown
- 1995-07-11 RU RU97101109/14A patent/RU2168982C2/en not_active IP Right Cessation
- 1995-07-11 EP EP95926249A patent/EP0804182B1/en not_active Expired - Lifetime
- 1995-07-11 AU AU30069/95A patent/AU703428B2/en not_active Ceased
- 1995-07-11 NZ NZ290050A patent/NZ290050A/en unknown
- 1995-07-11 DK DK95926249T patent/DK0804182T3/en active
- 1995-07-11 RO RO97-00128A patent/RO120041B1/en unknown
- 1995-07-11 HU HU9700238A patent/HU223841B1/en not_active IP Right Cessation
- 1995-07-11 AT AT95926249T patent/ATE218334T1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2526707T3 (en) | Purification and stabilization of peptides and proteins in pharmaceutical agents | |
RU99101790A (en) | METHOD FOR TREATING URINE INCOMPOSITION USING (S) -OXIBUTININ AND (S) -DESETHYLOXIBUTININ | |
EA200000468A1 (en) | THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY | |
RU96115200A (en) | 2,4-DISULFOFENYLBUTILNITRON, ITS SALT AND THEIR APPLICATION AS PHARMACEUTICAL SPIN TRAPS | |
RU93051780A (en) | CONTROLLED RELEASE COMPOSITIONS CONTAINING OXYCODONE, METHOD FOR REDUCING DAILY DOSES OF PRODUCTS CONTAINING OXYCODON | |
CO5261582A1 (en) | VALDECOXIB COMPOSITIONS | |
SE8306367L (en) | ANTIDIURETICALLY EFFECTIVE PHARMACEUTICAL PREPARATION | |
KR900003203A (en) | Neuropeptide Y antagonists and preparation methods thereof | |
EP0911331A3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
RU97101109A (en) | APPLICATION OF GABAPENTIN FOR TREATMENT OF FEAR AND PANIC CONDITIONS | |
RU94034109A (en) | AGENT FOR THE TREATMENT OF THE STATE OF ALARM | |
ATE361098T1 (en) | PREVENTION AND TREATMENT OF HYPERGASTRINEMIA | |
KR970061249A (en) | Compositions for Treating or Preventing Osteoporosis | |
RU97104483A (en) | SUITABLE ACID SALT 4- [2-AMINO-6- (CYCLOPROPYLAMINO) -9H-PURIN-9-IL] -2- CYCLOPENTEN-1-METHANOL AS ANTI-VIRUS AGENT | |
Shah et al. | Spinal and supraspinal effects of pertussis toxin on opioid analgesia | |
RU2005105691A (en) | Oral Administration of Calcitonin | |
RU96103685A (en) | 1,2,5-TIADIAZOLIC DERIVATIVES OF INDOLALALKYL-PYRIDINIL-PYRIMIDINIL-PIPERAZINES, METHOD OF TREATMENT OR PREVENTION OF THE DEVELOPMENT OF VASCULAR HEADACHE AND PHARMACEUTICAL COMPOSITION | |
RU97120700A (en) | NEW PHARMACOLOGICAL APPLICATION OF ANTAGONISTS A-II RECEPTOR | |
RU99100703A (en) | MODIFIED FORM OF HYDROCHLORIDE R (-) - N - (4,4-DI (3-METHYL-THIEN-2-IL) BUT-3-ENYL) -NIPECOTHIC ACID | |
KR900701278A (en) | Bile acids for the treatment of viral infections | |
US5055449A (en) | Vincristine-containing product | |
RU95112520A (en) | APPLICATION 4'-IODO-4'-DEOXIDOXORUBICINE FOR THE TREATMENT OF AMYLOIDOSIS, METHOD OF TREATMENT OF AMYLOIDOSIS | |
KR940005667A (en) | Linear peptide | |
US4143158A (en) | Inhibition of prolactin release by an opiate antagonist | |
KR950700063A (en) | Brofaromine as an agent for treating post-traumatic stress |